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Summary
The menstrual cycle increases insulin requirements in a
subset of women with type 1 diabetes as a result of re-
duced insulin action through sexual hormones. If exposure
to sexual hormones declines during the menopause,
adaptions of insulin dosing may be required. However,
there are no validated recommendations available on how
to adapt insulin treatment in postmenopausal women with
type 1 diabetes. The present study compared insulin dos-
ing profiles of 630 premenopausal and 548 post-
menopausal women, who had long-term type 1 diabetes
and used continuous subcutaneous insulin infusion. Data
were extracted from the German "Diabetes-Patienten-
Verlaufsdokumentation".
It was found that total daily insulin (p <0.0001), daily in-
sulin per kilogram bodyweight (p <0.0001), total daily
basal insulin (p <0.0001), daily basal insulin per kilogram
bodyweight (p <0.0001) and estimated glomerular filtration
rate (eGFR) (p <0.0001) were lower in postmenopausal
women. Total daily bolus insulin, daily bolus insulin per
kilogram, glycated haemoglobin A1, body mass index and
the incidence of severe hypoglycaemic events were simi-
lar in both cohorts.
Postmenopausal women with type 1 diabetes used lower
insulin doses as compared with premenopausal women,
whereas glycaemic control and body mass index were
comparable. This observation might be explained by lower
exposure to sexual hormones and lower eGFR, even
though the contribution of other factors such as body com-
position and eating habits requires further investigation.
Introduction
During the menstrual cycle higher insulin requirements
may occur in a subset of women with type 1 diabetes
(T1D) [1]. Subsequently, if menstrual cycles disappear
during the menopause, previously higher insulin require-
ments might decrease in parallel. To date, there is little
knowledge about how the menopause affects actual insulin
dosing in T1D. Irrespective thereof, the life expectancy of
patients with T1D tends to increase, and both age and the
duration of T1D correlate to a higher risk of acute com-
plications. In the T1D Exchange study, severe hypogly-
caemic events were most frequent in participants >50 years
of age, accounting for 15% of the entire study popula-
tion [2]. In the UK Hypoglycaemia Study, the prevalence
of severe hypoglycaemia was highest among adults with
a T1D duration >15 years [3]. As the natural menopause
occurs around the age of 50, postmenopausal women with
long-term T1D are particularly exposed to a higher risk for
acute complications. It is clinically well recognised that
T1D-related treatment adaptions become necessary during
and after the menopausal transition. However, there are
no treatment guidelines available on how to adapt insulin
treatment in postmenopausal women with T1D. It is there-
fore relevant to increase knowledge about postmenopausal
insulin dosing in order to reduce the risk of adverse glu-
cose fluctuations. The present study compared insulin dos-
ing profiles of pre- and postmenopausal women with long-
term T1D, who were using continuous subcutaneous
insulin infusion.
Methods
Data from 1686 women were extracted from the "Diabetes
Prospective Follow-up" ("Diabetes-Patienten-Verlaufs-
dokumentation" DPV) registry. The DPV database is a
standardised, prospective, computer-based documentation
of diabetes care and clinical outcomes. During 1995–2019,
1686 adult women aged ≥35 years with T1D from 420
centers in Germany, Austria and Switzerland were doc-
umented. Inclusion criteria were diagnosis of type1 dia-
betes (T1D), age ≥35 years, use of an insulin pump for 24
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hours per day, and complete documentation of basal and
bolus insulin doses. The DPV registry does not routinely
collect the date of the last menstrual period, a key crite-
rion for the definition of naturally occurring menopause.
According to an individual participant meta-analysis of
117 epidemiological studies, age at natural menopause was
49.3 ± 4.6 years in 170,413 women. Of those, 15% (n =
26,285) women reported naturally occurring menopause
before age of 45 years, 75% (n = 127,984) between the
ages 45 and 54 years and 10% (n = 16,144) at age 55 years
or older [4]. Following the aforementioned results, we de-
fined 630 women aged <45 years as premenopausal and
548 women aged ≥55 years as postmenopausal. In order to
evaluate a potential effect for earlier menopause in women
with T1D, an additional comparison was made between
women <40 years of age (n = 340) and women aged 55
years or older. Women between ≥40 and <55 years of age
(n = 798) were excluded from this secondary analysis.
The following parameters were analysed: demographic da-
ta such as age and duration of T1D, anthropometric para-
meters such as weight, height and body mass index (BMI),
and clinical data such as total daily insulin, daily insulin
per kilogram bodyweight, total daily basal insulin, daily
basal insulin per kilogram bodyweight, total daily bolus
insulin, daily bolus insulin per kilogram bodyweight, the
percentage of glycated haemoglobin A1 (HbA1c), and
the estimated glomerular filtration rate (eGFR)The most
recent basal rate profile together with the total daily bolus
insulin dose documented for each patient in the DPV data-
base was used for analysis. EGFR was calculated based on
the equation of the Chronic Kidney Disease Epidemiolo-
gy Collaboration (CKD_EPI). The incidence of severe hy-
poglycaemic events and the incidence of hypoglycaemic
events with coma per patient per year was included in
the analysisif available.
All procedures involving human participants were in ac-
cordance with the ethical standards of the institutional and/
or national research committee and with the 1964 Helsinki
declaration and its later amendments.
Wilcoxon rank sum test was used to calculate cross-sec-
tional differences between pre- and postmenopausal
women. A p-value of less than 0.05 was considered signif-
icant. Bonferroni post-hoc correction was applied for the
number of tests performed, resulting in an alpha-level of
0.05/15 = 0.0033. Statistical analysis was carried out with
SAS Version 9.4 (SAS Institute Inc., Cary, NC, USA). Da-
ta are presented as mean and standard error.
Results
Table 1 illustrates demographic, clinical and anthropomet-
ric parameters in pre- and postmenopausal women. In post-
menopausal women, total daily insulin, daily insulin per
kilogram bodyweight, total daily basal insulin, daily basal
insulin per kilogram bodyweight, and eGFR were signifi-
cantly lower than in premenopausal women. Doses for to-
tal daily bolus insulin, daily bolus insulin per kilogram
bodyweight, the percentage of HbA1c, BMI, the inci-
dence of severe hypoglycaemic events, and the incidence
of hypoglycaemic events with coma per patient per year
were comparable between both cohorts.
Discussion
Postmenopausal women used lower basal insulin doses as
compared with premenopausal women, whereas glycaemic
control and BMI were comparable between the two co-
horts.
When using continuous glucose monitoring, fewer hypo-
glycaemic events, higher nocturnal glucose, and higher
postprandial glucose fluctuations were observed in pre-
menopausal women with T1D during the luteal phase of
their menstrual cycle [5]. This may be explained by higher
concentrations of progesterone near the time of ovulation
and during the luteal phase, which increases insulin resis-
tance [6]. Depot-administration of progesterone in healthy
women caused higher fasting plasma glucose concentra-
tions followed by a pronounced secretion of insulin [7].
Table 1:
Differences in demographic, clinical and anthropometric parameters between premenopausal women (age ≥35 to <45 years) and postmenopausal women (age ≥55 years).
Parameter Premenopausal women Postmenopausal women p-valuea
Number of patients 630 548 Not applicable
Age (years) 39.79 ± 0.12 64.44 ± 0.29 <0.0001
Duration of T1D (years) 21.60 ± 0.40 32.66 ± 0.66 <0.0001
Total daily insulin (IU) 41.29 ± 0.85 39.00 ± 1.27 <0.0001
Daily insulin/kg (IU) 0.57 ± 0.01 0.53 ± 0.02 <0.0001
Total daily basal insulin (IU) 21.26 ± 0.37 19.60 ± 0.48 <0.0001
Daily basal insulin/kg (IU) 0.29 ± 0.01 0.27 ± 0.12 <0.0001
Total daily bolus insulin (IU) 22.38 ± 0.68 21.94 ± 1.14 0.0107
Daily bolus insulin/kg (IU) 0.31 ± 0.01 0.30 ± 0.01 0.0092
HbA1c (%; mmol/mol) 7.61 ± 0.06 7.50 ± 0.05 0.7858
BMI (kg/m2) 26.23 ± 0.20 26.80 ± 0.22 0.0459
Body weight (kg) 73.04 ± 0.61 72.40 ± 0.63 0.4864
Body height (cm) 166.77 ± 0.28 164.36 ± 0.27 <0.0001
eGFRb (ml/min/1.73 m2 body surface) 90.80 ± 1.2 67.39 ± 1.18 <0.0001
Severe hypoglycaemia (/year) 0.25 ± 0.05 0.24 ± 0.03 0.4335
Hypoglycaemia with coma (/year) 0.05 ± 0.01 0.10 ± 0.02 0.0306
BMI = body mass index; eGFR = estimated glomerular filtration rate; HbA1c = glycated haemoglobin A1; T1D = type 1 diabetes
a Wilcoxon rank sum test. A p-value <0.05 was considered statistically significant. Bonferroni post hoc correction was applied for 15 tests performed (alpha-level of 0.05/15 =
0.0033 as level of significance).
b eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD_EPI) equation.
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Moreover, oestradiol was found to augment growth-hor-
mone secretion, which may reduce the glucose-lowering
effect of insulin in the luteal phase of the menstrual cy-
cle [8]. As progesterone and oestradiol levels decrease dur-
ing menopause, these hormonal changes may be one of
the reasons for the differences in insulin doses seen in this
study.
In addition, the comparatively lower glomerular filtration
rate (GFR) in women aged ≥55 years might have con-
tributed to their lower insulin requirements. Endogenously
secreted insulin is subject to substantial degradation in the
liver. However, exogenous insulin is primarily eliminated
by the kidney. Insulin is freely filtered at the glomerulus
and extensively reabsorbed in the proximal tubule. Within
proximal tubular cells, insulin undergoes enzymatic degra-
dation. Further insulin uptake and degradation is conduct-
ed by peritubular endothelial and renal epithelial cells,
which is why total renal clearance exceeds GFR [9]. Per-
itubular insulin absorption is indirectly correlated to renal
function, thereby compensating for the decline in degrada-
tion of filtered insulin down to a GFR of <20 ml/min. Be-
yond this threshold, insulin clearance decreases, the half-
life of insulin increases and overall requirements for
insulin decline [10–12]. The decreased clearance and ca-
tabolism of insulin may ultimately translate into longer
persistence of short- and long-acting insulin preparations
and increase the risk for hypoglycaemia. Kulozik et al. in-
vestigated the correlation of eGFR and required doses of
long- and short-acting insulin analogues in over 300 pa-
tients with T1D. Requirements for insulin lispro were di-
rectly correlated to the whole range of eGFR. In patients
with eGFR <60 ml/min, insulin dosage was 32.6% lower
than in patients with eGFR >90 ml/min. However, require-
ments for insulin aspart were independent of eGFR [13].
In the present study, mean eGFR was >50 ml/min, below
which substantial reductions of insulin dosing are recom-
mended and both cohorts presented a similar risk for se-
vere hypoglycaemic events [14]. Moreover, insulin aspart
was commonly used in the older cohort, which might fur-
ther influence the extent to which insulin doses were re-
duced. In summary, the decline in renal function observed
in women aged ≥55 years may have contributed to reduc-
tions of their daily insulin doses. Yet the net effect of renal
function on insulin adaptions should be interpreted with
consideration of other factors determining insulin require-
ments in younger and older women.
One of these factors may be a change in caloric intake
after the menopause. Changes in appetite and caloric intake
are commonly observed during the menstrual cycle. The
largest clinical trial on macronutrient intake in pre-
menopausal women - the BioCycle study - revealed the
following: caloric intake and appetite, as well as craving
for chocolate, sweet and salt peaked during the mid-luteal
phase in 259 women, regardless of whether ovulation ac-
tually occurred or not [15].The impact of oestrogen and
progesterone together with changes in eating habits may
increase insulin requirements, particularly during the luteal
phase of the menstrual cycle. In an analysis of blood sam-
ples obtained from the BioCycle study, a homeostasis mod-
el of insulin resistance (HOMA-IR) significantly increased
from 1.4 during the mid-follicular phase to 1.6 in the early
luteal phase of the menstrual cycle (p <0.001). After ad-
justment for age, race, cycle and other sex hormones,
HOMA-IR was positively associated with oestradiol (p
<0.001) and progesterone (p <0.001) [6]. A study using
continuous glucose monitoring in 12 women with T1D,
who were treated with continuous subcutaneous insulin in-
fusion, showed elevated high blood glucose indices dur-
ing periovulation and until the early luteal phase [1]. In
summary, premenopausal women may require higher in-
sulin doses to compensate for changes in insulin action and
caloric consumption during the menstrual cycle. After the
menopause, these effects disappear, which might explain
the use of lower insulin doses in postmenopausal women.
BMI was similar in both cohorts, which indicates that the
observed differences in insulin doses were independent of
body weight. However, BMI does not reflect body com-
position, which might change during transition to the
menopause. Data from the longitudinal Study of Women’s
Health Across the Nation (SWAN), which measured body
composition during the menopausal transition in 1246
women showed the following: at the start of menopausal
transition, the rate of body fat gain doubled, whereas a sig-
nificant loss of lean mass was observed. These changes
continued until 2 years after the last menstrual bleeding
was observed and stabilised afterwards [16]. An increase
in body fat mass would likely associate with higher insulin
requirements. However, body composition was not ob-
tained in the present study, which precludes estimation
ofits contribution to the observed changes in insulin re-
quirements.
The study is subject to the following limitations. First,
this was a cross-sectional study, which precludes analy-
sis of changes in insulin dosing profilesprior, during or af-
ter transition to the menopause. Nevertheless, bolus insulin
doses, HbA1c and BMI were comparable between the two
cohorts, which indicates that the observed results were in-
dependent of nutrition, glycaemic control and body
weight. Second, the DPV database did not include infor-
mation about the last menstrual period. However, the de-
finition of the menopause in the present study was based
on the age of natural occurrence of the menopause in
>118,000 women from 117 epidemiological studies, which
should reduce the number of women falsely defined as pre-
or postmenopausal to a minimum. Information about the
final menstrual period would furthermore have identified
cases of early menopause. Women with T1D have a high-
er prevalence of early menopause, which may be related
to prolonged hyperglycaemia, long-term complications of
T1D, or autoimmune processes directed against the ovary
[17–21]. In order to evaluate a potential influence of early
menopause, we conducted a comparison of women <40
years of age with women aged ≥55 years. The subanalysis
revealed similar resultsto our main analysis, with signifi-
cant differences in total daily insulin and basal insulin dos-
es (please refer to supplementary table 1 in the appendix).
Third, the DPV database did not provide the number of
basal rates used by premenopausal women. Multiple basal
rates may be used by women with T1D to compensate for
variable insulin requirements during the menstrual cycle. If
the last basal rate profile entered in the DPV database was
a profile that is commonly used outside of the menstrual
cycle, it likely provided lower basal insulin doses accord-
ing to higher insulin requirements during the menstrual cy-
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cle. In this case, the present results were rather underesti-
mated. Fourth, the DPV database does not routinely obtain
information about the intake of hormone replacement ther-
apy [HRT), which was associated with a reduction of in-
sulin requirements in postmenopausal women [22]. HRT
is used independently of diabetes in women in order to
treat symptoms associated with the menopausal transition.
In order to increase representability of the present re-
sults, HRT was not an exclusion criterion in the present
study.
In summary, postmenopausal women with T1D used lower
basal insulin dose profiles as compared with pre-
menopausal women, despite similar glycaemic control and
BMI. Lower eGFR and lower exposure to sexual hormones
may be responsible for this observation. However, further
research is necessary to determine the contribution of body
composition and eating habits to the observed difference in
daily insulin doses.
The data that support the findings of this study are avail-
able on request from the corresponding author. The data
are not publicly available due to privacy or ethical restric-
tions.
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Appendix: Supplementary table
Supplementary table S1 illustrates differences between premenopausal and postmenopausal women.
Table S1:
Differences in demographic, clinical, and anthropometric parameters between premenopausal women (age ≥ 35 to <40 years) and postmenopausal women (age ≥ 55 years).
Parameter Premenopausal women Postmenopausal women p-valuea
Number of patients 340 548 Not applicable
Age (years) 37.38 ± 0.08 64.44 ± 0.29 <0.0001
Duration of T1D (years) 20.16 ± 0.51 32.66 ± 0.66 <0.0001
Total daily insulin (IU) 40.71 ± 1.01 39.00 ± 1.27 0.0004
Daily insulin/kg (IU) 0.56 ± 0.01 0.53 ± 0.02 0.0001
Total daily basal insulin (IU) 20.88 ± 0.49 19.60 ± 0.48 <0.0001
Daily basal insulin/kg (IU) 0.29 ± 0.01 0.27 ± 0.12 <0.0001
Total daily bolus insulin (IU) 22.28 ± 0.70 21.94 ± 1.14 0.0084
Daily bolus insulin/kg (IU) 0.31 ± 0.01 0.30 ± 0.01 0.0030
HbA1c (%; mmol/mol) 7.52 ± 0.08 7.50 ± 0.05 0.1931
BMI (kg/m2) 26.14 ± 0.28 26.80 ± 0.22 0.0495
Body weight (kg) 72.66 ± 0.82 72.40 ± 0.63 0.8823
Body height (cm) 166.67 ± 0.36 164.36 ± 0.27 <0.0001
eGFRb (ml/min/1.73 m2 body surface) 92.99 ± 1.62 67.39 ± 1.18 <0.0001
Severe hypoglycaemia (/year) 0.32 ± 0.09 0.24 ± 0.03 0.9556
Hypoglycaemia with coma (/year) 0.06 ± 0.01 0.10 ± 0.02 0.1350
T1D = type 1 diabetes; HbA1c = haemoglobin A1; BMI = body mass index; eGFR = estimated glomerular filtration rate
a Wilcoxon rank sum test. A p-value <0.05 was considered statistically significant. Bonferroni post hoc correction was applied for 15 tests performed (alpha-level of 0.05/15 =
0.0033 as level of significance).
b eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD_EPI) equation.
Original article Swiss Med Wkly. 2021;151:w30025
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution-NonCommercial-ShareAlike 4.0”.
No commercial reuse without permission. See https://smw.ch/permissions
Page 5 of 5
